Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 64.25 5.62% 3.42
ICPT closed up 5.62 percent on Tuesday, October 15, 2019, on 77 percent of normal volume.

Earnings due: Oct 29

*** please verify all earnings dates ***
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Up
See historical ICPT trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Multiple of Ten Bullish Other 5.62%
Outside Day Range Expansion 5.62%
Up 3 Days in a Row Strength 5.62%
Oversold Stochastic Weakness 5.62%
Slingshot Bearish Bearish Swing Setup 7.89%
NR7 Range Contraction 7.89%

Older signals for ICPT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
ICPT Chart by TradingView
Basic chart:
Profile
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Medical Specialties Diabetes Gastroenterology Hepatology Digestive Diseases Fibrosis Primary Biliary Cholangitis Bile Acid Chronic Liver Diseases Obeticholic Acid
Is ICPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 11 Startup with eye on fatty liver disease NASH lays out $70M IPO plan
Sep 27 Intercept Pharma files U.S. application for obeticholic acid for NASH
Sep 27 Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASH
Sep 26 Enanta's Stock Down Despite NASH Drug Meeting Goal in Study
Sep 26 Why This Biotech Stock Just Opened At Its Lowest Point In Nearly 2 Years
Sep 25 Intercept to Present at Upcoming Investor Conference in October
Sep 13 Who Has Been Selling Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares?
Sep 11 Intercept Launches NASHTRUTH.com, an Online Educational Resource for People with Advanced Fibrosis Due to NASH
Sep 9 Better Buy: Intercept Pharmaceuticals vs. Viking Therapeutics
Sep 9 Intercept Appoints Lisa DeFrancesco as Vice President, Investor Relations
See more ICPT news...
Indicators
Indicator Value
52 Week High 131.87
52 Week Low 56.76
Average Volume 485,983
200-Day Moving Average 86.9017
50-Day Moving Average 64.5574
20-Day Moving Average 63.996
10-Day Moving Average 61.264
Average True Range 2.9074
ADX 21.05
+DI 20.0583
-DI 25.1467
Chandelier Exit (Long, 3 ATRs ) 64.2578
Chandelier Exit (Short, 3 ATRs ) 65.4822
Upper Bollinger Band 71.2184
Lower Bollinger Band 56.7736
Percent B (%b) 0.52
BandWidth 22.571411
MACD Line -1.4934
MACD Signal Line -1.2816
MACD Histogram -0.2118
Fundamentals Value
Market Cap 1.61 Billion
Num Shares 25.1 Million
EPS -15.49
Price-to-Earnings (P/E) Ratio -4.15
Price-to-Sales 20.99
Price-to-Book 8.77
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 69.84
Resistance 3 (R3) 69.27 66.84 68.91
Resistance 2 (R2) 66.84 65.41 67.12 68.60
Resistance 1 (R1) 65.54 64.53 66.19 66.11 68.29
Pivot Point 63.11 63.11 63.43 63.39 63.11
Support 1 (S1) 61.82 61.69 62.46 62.39 60.21
Support 2 (S2) 59.38 60.81 59.67 59.90
Support 3 (S3) 58.09 59.38 59.59
Support 4 (S4) 58.66